Alidac Pharmaceuticals Profile
Key Indicators
- Authorised Capital ₹ 100.00 Cr
as on 26-04-2024
- Paid Up Capital ₹ 99.33 Cr
as on 26-04-2024
- Company Age 19 Year, 2 Months
- Last Filing with ROC 31 Mar 2019
- Satisfied Charges ₹ 35.00 Cr
as on 26-04-2024
- Revenue -59.96%
(FY 2019)
- Profit -188.65%
(FY 2019)
- Ebitda -186.04%
(FY 2019)
- Net Worth -12.14%
(FY 2019)
- Total Assets -3.61%
(FY 2019)
About Alidac Pharmaceuticals
- CIN/LLPIN
U24230GJ2005PLC046915
- Company No.
046915
- Company Classification
Public Limited Indian Non-Government Company
- Incorporation Date
14 Oct 2005
- Date of AGM
30 Jul 2019
- Date of Balance Sheet
31 Mar 2019
- Listing Status
Unlisted
- ROC Code
Roc Ahmedabad
Industry
Company Details
- Location
Ahmedabad, Gujarat, India
- Telephone
- Email Address
- Website
-
- Social Media-
Who are the key members and board of directors at Alidac Pharmaceuticals?
Executive Team (3)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
| Dhavlal Soni | Company Secretary | 07-Feb-2019 | Current |
| Jignesh Thosani | CFO | 01-Feb-2019 | Current |
| Satyanarayan Sathe | CEO | 30-Mar-2019 | Current |
Board Members(4)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Nitinkumar Parekh  | Director | 17-Jun-2014 | Current |
| Kshitish Shah | Director | 27-Jul-2015 | Current |
| Ganesh Nayak | Director | 07-Apr-2006 | Current |
| Subodhchandra Adeshara | Director | 27-Jul-2015 | Current |
Financial Performance of Alidac Pharmaceuticals.
Alidac Pharmaceuticals Limited, for the financial year ended 2019, experienced significant reduction in revenue, with a 59.96% decrease. The company also saw a substantial fall in profitability, with a 188.65% decrease in profit. The company's net worth observed a substantial decline by a decrease of 12.14%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metric |
| (FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue |
| ||||||
| Revenue from Operations |
| ||||||
| Total Assets |
| ||||||
| Profit or Loss |
| ||||||
| Net Worth |
| ||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of Alidac Pharmaceuticals?
In 2019, Alidac Pharmaceuticals had a promoter holding of 100.00%. Access key insights, ownership, including shareholding patterns, funding, foreign investors, KMP remuneration, group structure, and overseas investments.
Related Corporates (Common Directorship)
Zydus Hospira Oncology Private LimitedActive 19 years 6 monthsGanesh Nayak and Nitinkumar Parekh are mutual person
- Zydus Pharmaceuticals LimitedActive 4 years 11 months
Dhavlal Soni and Jignesh Thosani are mutual person
Charges (Loans)
| Lender | Amount | Status |
|---|---|---|
Export-Import Bank Of India Creation Date: 25 Aug 2008 | ₹35.00 Cr | Satisfied |
How Many Employees Work at Alidac Pharmaceuticals?
Alidac Pharmaceuticals has a workforce of 242 employees as of Apr 07, 2024. Unlock access to detailed historical data on individuals associated with the company, including employment records, contributions to the Employees' Provident Fund Organization (EPFO), and other related insights.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Alidac Pharmaceuticals, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Alidac Pharmaceuticals's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.
